"Increased value for Patriot Scientific shareholders is our fundamental driver," Pohl continued. "While the very busy Alliacense team negotiates with more and more global manufacturers to become licensees of our jointly owned patent portfolio, the Patriot management and board are pursuing the other prong of our two-fold strategy by engaging in ongoing negotiations for a potential joint venture to enhance our Ignite(TM) chip as well as engaging in communications with another technology company whose attractive potential may lead to an investment or acquisition by Patriot."